Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.

Irene SchiavettiCinzia CordioliMaria Laura StromilloMaria Teresa FerròAlice Laroni Eleonora CoccoGaia ColaLivia PasqualiMaria Teresa RillaElisabetta SignorielloRosa IodiceAlessia Di SapioRoberta LanzilloFrancesca CaleriPietro AnnovazziAntonella ConteGiuseppe LiberatoreFrancesca RuscicaRenato DocimoSimona BonavitaMonica UlivelliPaola CavallaFrancesco PattiDiana FerraroMarinella ClericoPaolo ImmovilliMassimiliano Di FilippoMarco Salvetti Maria Pia Sormani

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2022)

The risk of breakthrough SARS-CoV-2 infections is higher in patients treated with ocrelizumab and fingolimod, and the rate of severe infections was significantly reduced in all the DMTs excluding ocrelizumab.

Keyphrases

sars cov
multiple sclerosis
respiratory syndrome coronavirus
ejection fraction
newly diagnosed
mass spectrometry
prognostic factors
ms ms
patient reported outcomes